Division of Basic Medical Research FY2021 List of Projects - Research Program on Hepatitis

Program for Basic and Clinical Research on Hepatitis

First Year	Principal Investigator	Affiliation		Project Title
FY2019	ENOMOTO Nobuyuki	University of Yamanashi	Director	Study on factors influencing post treatment pathological status in hepatitis C patients receiving direct acting antiviral agents using next generation sequencing technology
FY2019	TANAKA Yasuhito	Kumamoto University	Professor	Genome-wide research aimed at identifying host factors affecting the changes in disease conditions after direct acting antiviral therapies for hepatitis C
FY2019	KANEKO Shuichi	Kanazawa University	Professor	Study of preventing hepatocarcinogenesis from chronic hepatitis C
FY2019	KAWADA Norifumi	Osaka City University	Professor	Study on the development of regression therapy for liver fibrosis by using recombinant human Cytoglobin
FY2019	OHDAN Hideki	Hiroshima University	Professor	Research and development of immune-therapy using pluripotent stem cells as potential anti-hepatitis/hepatoma therapeutics
FY2019	KATO Naoya	Chiba University	Professor	Development of Hepatocarcinogenesis Prevention in Hepatitis C by Activating Innate Immune Response
FY2019	MURAMATSU Masamichi	National Institute of Infectious Diseases	Director	Basic research and development of novel diagnostic and therapeutic approaches for viral hepatitis
FY2019	OTSUKA Motoyuki	The University of Tokyo	Assistant Professor	Development of novel interventional methods against hepatitis B based on the comprehensive elucidation of its pathogenesis
FY2019	OKAMOTO Toru	Osaka University	Professor	Development of novel therapeutics for pathogenesis induced by hepatitis viruses
FY2019	TOKUNAGA Katsushi	National Center for Global Health and Medicine	Co-Director, Genome Medical Science Project	Study for clinical sequencing based on genome analysis of host and viral factors
FY2019	YAMAMOTO Takuya	National Institutes of Biomedical Innovation, Health and Nutrition	Project Leader	Establishment of therapeutic strategies toward a functional cure for HBV by innovative immunotherapies
FY2019	TAKEHARA Tetsuo	Osaka University	Professor	Study of outcome of liver cirrhotic patients received HCV elimination therapy
FY2019	NAKAGAWA Hayato	The University of Tokyo	Specially Appointed Lecturer	Relevance of burned-out phenomenon to the pathogenesis of NASH: Development of a new therapeutic strategy based on lipid metabolism
FY2019	ASAHINA Yasuhiro	Tokyo Medical and Dental University	Professor	Development of an innovative disease model using human iPS cell-derived liver organoids and creation of treatments to suppress hepatic fibrosis and hepatocarcinogenesis
FY2019	SUGIYAMA Masaya	National Center for Global Health and Medicine	Vice Director	Development of full-length HBV-POL expression system for drug discovery
FY2019	YAMANE Daisuke	Tokyo Metropolitan Institute of Medical Science	Chief Researcher	Study of Intrinsic Antiviral Signaling Pathways in Hepatocytes Toward the Development of Novel Antiviral Strategies
FY2019	TAKAYAMA Kazuo	Kyoto University	Junior Assistant Professor	Functional analysis and regulation of liver disease-associated gene TLL1
FY2020	TAKEHARA Tetsuo	Osaka University	Professor	Elucidation of the progression of liver pathology such as liver carcinogenesis after hepatitis C virus elimination and its predictors
FY2020	CHAYAMA Kazuaki	Hiroshima University	Professor	Study of factors associated with health status and prognosis after successful HCV eradication
FY2020	AIZAKI Hideki	National Institute of Infectious Disease	Chief	Study on pathology and course of liver carcinogenesis after sustained virologic response in hepatitis C
FY2020	KUROSAKI Masayuki	Musashino Red Cross Hospital	Vice President	Study on the effect of resistance associated substitutions on clinical features of hepatitis C virus infection
FY2020	TAJIRI Hitoshi	Kindai University Nara Hospital	Researcher	Studies on evaluation of progression of viral hepatitis during childhood and on development of treatment strategy
FY2020	YATSUHASHI Hiroshi	National Hospital Organization Nagasaki Medical Center	Vice President	Study of contributing to improvement of QOL and improvement of prognosis in patients with liver cirrhosis
FY2020	TERAI Shuji	Niigata University	Professor	Translational research aiming for development of next generation exosome therapy for cirrhosis
FY2020	OSAFUNE Kenji	Kyoto University	Professor	Development of cell therapy against liver cirrhosis using human iPS cells and nonhuman primate liver disease models
FY2020	SAKAMOTO Naoya	Hokkaido University	Professor	Screening of prognostic biomarker by comprehensive serum and liver tissue glycomics
FY2020	HONDA Masao	Kanazawa University	Professor	Revealing the association of impaired barrier function of liver sinusoidal endothelial cells and the onset of lifestyle disease related non-B, non-C hepatitis and hepatocellular carcinoma
FY2020	KODAMA Takahiro	Osaka university	Assistant professor	Study of molecular mechanisms of NASH and non-B non-C liver cancer and exploration of their therapeutic targets
FY2020	KANDA Tatsuo	Nihon University School of Medicine	Associate Professor	Research and development of infection prevention, pathological mechanism, diagnosis and treatment for hepatitis A and E viruses
FY2020	UENO Hideki	Kyoto University	Professor	Promoting HBs seroconversion in chronic HBV infection
FY2020	NAKAMOTO Yasunari	University of Fukui	Professor	Development of Novel Targeted Immunotherapy for Chronic Hepatitis B to Regulate both Virus and Carcinogenesis
FY2020	NISHIDA Nao	National Center for Global Health and Medicine	Senior Researcher	Predictive Model to Prevent Development of Liver Disease Based on the Polygenic Risk Score (PRS)
FY2020	MIYOSHI Eiji	Osaka University Graduate School of Medicine	Professor	Study of novel hepatocarcinogenesis mechanism using glycotechnology and its application
FY2020	SEKIBA Kazuma	The University of Tokyo	Staff Doctor	Comprehensive identification of host factors maintaining HBV cccDNA by CRISPR technology for the development of new therapeutic methods
FY2020	MURAI Kazuhisa	Kanazawa University	Assistant Professor	Establishment of the research infrastructure for liver cancer microenvironment and exploratory research of a novel cancer immunotherapeutic target
FY2020	ABE Yuichi	Aichi Cancer Center Research Institute	Senior Scientist	Screening of novel diagnostic markers and therapeutic targets for NASH-derived hepatocellular carcinoma by ultra-sensitive multi-omics
FY2021	HIASA Yoichi	Ehime University	Professor	Development of immune therapy to achieve drug-free for the patient with chronic hepatitis B
FY2021	SUZUKI Fumitaka	Toranomon Hospital	Director	The analyses of factors associated with drug free status and try to establish the therapies for setting out to drug free status and HBsAg
FY2021	MIZOKAMI Masashi	National Center for Global Health and Medicine	Project Leader	Development of cost-effective prophylaxis and treatment for hepatitis B virus (HBV) reactivation
FY2021	SUZUKI Tetsuro	Hamamatsu University School of Medicine	Professor	Development of a novel class of anti-HCV agents targeting the viral NS2
FY2021	SAKAI Katsuya	Kanazawa University	Associate Professor	A versatile hepatitis treatment based on recovery from liver dysfunctions and fibrosis achieved by an engineered
FY2021	MIZUGUCHI Hiroyuki	Osaka University	Professor	Development of hepatic tissue derived organoids for the novel treatment of cirrhosis and liver failure
FY2021	KANEYAMA Shuri	Showa University School of Medicine	Associate Professor	Development of the antisense nucleic acid aiming to treat liver fibrosis via extracellular matrix remodeling
FY2021	KOIKE Kazuhiko	The University of Tokyo	Professor Emeritus	Study of pathogenesis of metabolism-associated liver cancer on the background of steatohepatitis
FY2021	KANTO Tatsuya	National Center for Global Health and Medicine	Director General	Development of medicine for NASH patients with liver cancer based on inflammaging lipid-genomics research 2.0
FY2021	OTSUKA Motoyuki	The University of Tokyo	Assistant Professor	Elucidation of the mechanisms of chronic inflammation-induced hepatocarcinogenesis and development of novel
FY2021	NAKATSURA Tetsuya	National Cancer Center	Chief	Development of technology to suppress the onset and recurrence of liver cancer with circulating tumor cells and personalized immunotherapy
FY2021	YOSHIO Sachiyo	National Center for Global Health and Medicine	Chief	Development of novel therapy for the patients with chronic liver disease based on comprehensive understanding of muscle-liver-metabolism axis and immune system
FY2021	YAMASHITA Taro	Kanazawa University Hospital	Associate Professor	Development of a novel synthetic ligand optimized for the activation of hepatocyte nuclear factor 4α, a master regulator of liver metabolism, regeneration, and carcinogenesis, to develop an innovative treatment strategy on liver cancer
FY2021	NAKAMOTO Nobuhiro	Keio University	Associate Professor	Study to elucidate the mechanism of liver fibrosis and resolution via inter-organ network
FY2021	YOSHIJI Hitoshi	Nara Medical University	Professor	Development research of novel pathophysiology and therapy for hepatorenal syndrome in cirrhosis -Thrombotic microangiopathy and recombinant ADAMTS13 therapy-
FY2021	SHIOZAWA Yusuke	Nippon Medical School	Assistant Professor	Specific excision of hepatitis B virus covalently closed circular DNA using Cas9 nickase
FY2021	MATSUMOTO Tomonori	Osaka University	Assistant Professor	Exploration of novel treatment strategies for drug resistance and emergence of liver cancers targeting ploidy alterations and senescence escape
FY2021	Xian Yang QIN	RIKEN	Research Scientist	Molecular pathology and drug discovery of liver cancer by tracing dynamic changes of cancer stem cell marker expression

Program on the Innovative Development and the Application of New Drugs for Hepatitis B

First Year	Principal Investigator	Affiliation		Project Title
FY2017	TANAKA Yasuhito	Kumamoto University	Professor	Drug screening for developing HBV therapeutics and optimization of the hit compounds
FY2017	MORIYA Kyoji	The University of Tokyo	Professor	Search for drug candidates with novel mechanisms capable of efficient inhibition of hepatitis B virus propagation
FY2017	MURAMATSU Masamichi	National Institute for Infectious Diseases	Director	Basic research on hepatitis B virus life cycle and anti-viral development
FY2017	KATSUJI Kunio	Kobe University	Professor	Analysis of HBV life cycle by using sophisticated reporter HBV systems and its application to the development of a new strategy to suppress HBV infection and replication
FY2017	UEDA Keiji	Osaka University	Professor	Exploitation of anti-HBV strategies by targeting cellular factors functioning in the HBV life cycle
FY2017	KANTO Tatsuya	National Center for Global Health and Medicine	Director General	Establishment of novel therapeutic strategies against HBV - An integrated Immuno-omics approach
FY2017	FUJITA Takashi	Kyoto University	Visiting Professor	Research for HBV therapy development based on the establishment of HBV-sensitive cell and animal models
FY2017	TAKEHARA Tetsuo	Osaka University	Professor	Development of molecular pathogenesis and drug discovery using HBV infection models
FY2017	CHAYAMA Kazuaki	Hiroshima University	Professor	Hepatitis B virus eradication therapy development using a highly efficient cell culture system and a long term active chronic hepatitis B mouse model
FY2017	KANEKO Shuichi	Kanazawa University	Professor	Development of new antiviral therapies for hepatitis B virus
FY2017	MIZOKAMI Masashi	National Center for Global Health and Medicine	Project Leader	Comprehensive development of innovative therapeutic methods for complete inactivation of the HBV genome in the liver through application of genome-editing technology in personalized medicine
FY2017	MATSUURA Tomokazu	RIKEN	Visiting Senior Researcher	Drug discovery researches for licensing-out the next generation anti-HBV drugs
FY2017	MITSUYA Hiroaki	Kumamoto University	Distinguished Guest Professor	Development of novel anti-hepatitis B virus (HBV) agents potent against wild-type- and drug-resistant-HBVs
FY2017	WATASHI Koichi	National Institute of Infectious Diseases	Senior Researcher	Drug development against hepatitis B virus using chemical biological approaches and mathematical models
FY2017	ITO Kiyoaki	Aichi Medical University	Professor	Regulation of hepatitis B virus targeting by the control mechanisms of bile acid metabolism

Last updated 05/25/21